CFD 属于复杂的高风险金融工具,其杠杆作用可能导致投资者迅速亏损。 84% 的散户投资者因进行 CFD 交易遭受资金损失。 请您谨慎考虑自己是否了解 CFD 操作,以及是否能够接受高额亏损的风险。

交易 ABVC BioPharma, Inc. - ABVC CFD

-
0%
  • 概括
  • 历史数据
  • 活动
  • 收入报表
  • 资产负债表
  • 现金流
  • 所有权
交易条件
价差 -
多头隔夜费

Long position overnight fee


Margin. Your investment $1,000.00
隔夜费用 -0.025457 %
Charges from borrowed part ($-1.02)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

前往平台
-0.025457%
空头隔夜费

Short position overnight fee


Margin. Your investment $1,000.00
隔夜费用 0.003235 %
Charges from borrowed part ($0.13)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

前往平台
0.003235%
隔夜费时间 21:00 (UTC)
最小交易量 1
货币 USD
保证金 20%
上市交易所 United States of America
交易费 0%

*Information provided by Capital.com

关键数据
前收盘价* N/A
开仓* N/A
1 年变化* N/A
日范围* N/A
52 周范围 0.50-2.10
平均交易量(10 天) 37.24K
平均交易量(3 个月) 845.96K
市值 22.17M
市盈率 -100.00K
流通股 33.08M
收入 1.07M
EPS -0.38
股息(收益率 %) N/A
贝塔 0.42
下一个财报发布日期 Aug 14, 2023

所有数据都是由Refinitiv提供的, 除了标有星号的数据, 这是*由 Capital.com 提供的数据

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date 平仓 Change Change (%) 開倉 High Low

ABVC BioPharma, Inc. Events

时间(协调世界时) (UTC) 国家/地区 事件
Monday, August 14, 2023

时间(协调世界时) (UTC)

10:59

国家/地区

US

事件

Q2 2023 ABVC Biopharma Inc Earnings Release
Q2 2023 ABVC Biopharma Inc Earnings Release

Forecast

-

Previous

-
Monday, November 13, 2023

时间(协调世界时) (UTC)

21:00

国家/地区

US

事件

Q3 2023 ABVC Biopharma Inc Earnings Release
Q3 2023 ABVC Biopharma Inc Earnings Release

Forecast

-

Previous

-
查看所有活動
  • 年度
  • 每季度
2022 2021 2020 2019 2018
总收入 0.96978 0.3558 0.48305 0.70172 0.00696
收入 0.96978 0.3558 0.48305 0.70172 0.00696
收入成本,共计 0.28642 0.00509 0.01872 0.02014 0.18528
毛利 0.68336 0.35071 0.46433 0.68158 -0.17832
总营业费用 16.1943 12.0618 9.95004 4.1605 5.40463
销售/一般/行政费用,总计 13.1043 11.0529 8.42045 3.09181 1.61752
研究与开发 2.69346 1.00381 0.54966 1.04855 0.98872
营业收入 -15.2245 -11.706 -9.46699 -3.45878 -5.39767
利息收入(费用),非经营净值 -0.37306 -0.02754 -1.54658 -0.66835 -1.03872
税前净收入 -15.5146 -11.2108 -10.8139 -4.01028 -6.42963
税后净收入 -16.3124 -12.0358 -10.5936 -3.93324 -6.06453
未计算非常项目前的净收益 -16.4232 -12.8388 -9.79116 -3.64178 -5.57538
净收入 -16.4232 -12.8388 -9.79116 -3.64178 -5.57538
普通股股东可获收益 (不含非经常性项目) -16.4232 -12.8388 -9.79116 -3.64178 -5.57538
普通股股东可获收益 (含非經常性項目) -16.4232 -12.8388 -9.79116 -3.64178 -5.57538
摊薄净收入 -16.4232 -12.8388 -9.79116 -3.64178 -5.57538
摊薄后加权平均股 31.6647 25.0535 19.7156 17.4985 11.6071
扣除特别项目的每股摊薄盈利 -0.51866 -0.51246 -0.49662 -0.20812 -0.48034
每股正常摊薄盈利 -0.5164 -0.51246 -0.46493 -0.20812 -0.33401
非常规项目总计
Dividends per Share - Common Stock Primary Issue
异常费用(收入) 0.11013 0 0.96122 2.61311
其他,净值 0.083 0.52268 0.19964 0.11685 0.00677
少数股东权益 -0.11087 -0.80296 0.80242 0.29146 0.48915
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
总收入 0.12827 0.58899 0.04227 0.31286 0.02566
收入 0.12827 0.58899 0.04227 0.31286 0.02566
收入成本,共计 0.06024 0.26541 0.01074 0.00837 0.0019
毛利 0.06803 0.32358 0.03153 0.30449 0.02376
总营业费用 2.03446 3.83211 3.75811 2.35972 6.24438
销售/一般/行政费用,总计 1.63924 1.96079 3.44189 1.81857 5.88308
研究与开发 0.33498 1.49579 0.30548 0.53278 0.3594
营业收入 -1.90619 -3.24312 -3.71584 -2.04686 -6.21872
利息收入(费用),非经营净值 -0.01621 -0.35877 -0.07855 0.03473 0.02953
其他,净值 0.02517 0.06386 0.02209 -0.01766 0.01471
税前净收入 -1.89723 -3.53803 -3.7723 -2.02978 -6.17448
税后净收入 -1.89723 -4.5009 -3.77652 -1.94733 -6.08762
少数股东权益 0.07354 -0.36304 0.07166 0.08834 0.09218
未计算非常项目前的净收益 -1.8237 -4.86394 -3.70486 -1.859 -5.99544
净收入 -1.8237 -4.86394 -3.70486 -1.859 -5.99544
普通股股东可获收益 (不含非经常性项目) -1.8237 -4.86394 -3.70486 -1.859 -5.99544
普通股股东可获收益 (含非經常性項目) -1.8237 -4.86394 -3.70486 -1.859 -5.99544
摊薄净收入 -1.8237 -4.86394 -3.70486 -1.859 -5.99544
摊薄后加权平均股 33.0758 33.0784 32.5746 31.3073 29.6834
扣除特别项目的每股摊薄盈利 -0.05514 -0.14704 -0.11373 -0.05938 -0.20198
Dividends per Share - Common Stock Primary Issue 0 0 0 0
每股正常摊薄盈利 -0.05514 -0.14488 -0.11373 -0.05938 -0.20198
异常费用(收入) 0.11013
  • 年度
  • 每季度
2022 2021 2020 2019 2018
流动资产总额 2.98725 9.62512 6.17297 0.87824 0.56648
现金和短期投资 0.16106 5.9367 4.27321 0.1443 0.22669
Cash
应收账款总额,净额 1.36949 1.71271 0.9994 0.64053 0.09848
Total Assets 9.85548 13.698 11.6067 6.92781 5.94012
Other Long Term Assets, Total 3.14966 1.14238 1.95543 1.63958 1.37541
Total Current Liabilities 5.81953 3.69231 4.84439 6.81419 10.9878
Accounts Payable 0 0.02304 0.024 0
Accrued Expenses 3.2789 1.6479 2.43503 2.31182 1.24316
Notes Payable/Short Term Debt 1.89375 1.64 1.8358 2.0187 1.4097
Other Current Liabilities, Total 0.64688 0.40441 0.30052 0.43877 7.7451
Total Liabilities 6.75689 4.85438 8.16837 7.07878 11.5981
Total Long Term Debt 0 0 2.6244 0 0.26526
Total Equity 3.09859 8.84365 3.43834 -0.15096 -5.658
Common Stock 0.03286 0.02893 0.02442 0.01948 0.01189
Additional Paid-In Capital 67.9075 58.1137 40.7518 28.1803 14.9837
Retained Earnings (Accumulated Deficit) -54.9044 -38.4812 -25.6424 -15.8512 -12.2094
Total Liabilities & Shareholders’ Equity 9.85548 13.698 11.6067 6.92781 5.94012
Total Common Shares Outstanding 32.8573 28.9263 24.4205 19.4782 11.8848
现金等价物 0.08527 5.82855 4.27321 0.1443 0.22669
Accounts Receivable - Trade, Net 0.85567 0.42609 0.30315 0.30684 0
Total Inventory 0 0.02598 0 0 0.00132
Prepaid Expenses 0.15024 1.21307 0.17219 0.07727 0.2239
Other Current Assets, Total 1.30646 0.73667 0.72816 0.01615 0.01609
Property/Plant/Equipment, Total - Net 1.73512 1.99778 2.28758 1.04538 0.51007
Property/Plant/Equipment, Total - Gross 5.03958 5.31225 5.58627 4.28667 0.76247
Accumulated Depreciation, Total -3.30446 -3.31447 -3.29869 -3.24129 -0.2524
Long Term Investments 0.84207 0.93276 1.19073 3.36462 3.48817
Current Port. of LT Debt/Capital Leases 0 0.25 2.0209 0.58984
Long Term Debt 0 2.6244 0 0.26526
Minority Interest 0.13755 0.02669 -0.77627 0.02615 0.31761
Other Liabilities, Total 0.79981 1.13538 1.47585 0.23844 0.02747
Treasury Stock - Common -9.1 -9.1 -9.1 -9.1 -9.1
Other Equity, Total -0.83731 -1.71774 -2.5955 -3.39957 0.65585
短期投资 0.0758 0.10815
Goodwill, Net 0
Preferred Stock - Non Redeemable, Net 0 0
Note Receivable - Long Term 1.14138
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
流动资产总额 3.48006 2.98725 2.90308 9.78939 7.98793
现金和短期投资 1.21297 0.16106 1.40113 2.99337 2.81349
现金等价物 1.13496 0.08527 1.32354 2.91061 2.71794
应收账款总额,净额 1.26231 1.36949 0.54768 4.14502 3.14197
Accounts Receivable - Trade, Net 0.74233 0.85567 0.04768 0.4317 0.4266
Total Inventory 0 0.02049 0.02186 0.0227
Prepaid Expenses 0.34785 0.15024 0.28718 1.94052 1.29512
Other Current Assets, Total 0.65692 1.30646 0.6466 0.68863 0.71465
Total Assets 10.7349 9.85548 10.4806 13.7826 12.0668
Property/Plant/Equipment, Total - Net 1.67034 1.73512 1.81068 1.89187 1.98134
Property/Plant/Equipment, Total - Gross 4.98422 5.03958 5.09896 5.19408 5.29062
Accumulated Depreciation, Total -3.31388 -3.30446 -3.28828 -3.30221 -3.30928
Long Term Investments 0.84984 0.84207 0.81616 0.87057 0.90425
Other Long Term Assets, Total 3.48877 3.14966 3.76069 1.23078 1.19323
Total Current Liabilities 5.07494 5.81953 3.89431 3.64586 3.6637
Accounts Payable 0.00209
Payable/Accrued
Accrued Expenses 3.1506 3.2789 1.56525 1.59718 1.59657
Notes Payable/Short Term Debt 0.902 1.89375 1.86625 1.574 1.60975
Current Port. of LT Debt/Capital Leases
Other Current Liabilities, Total 1.02233 0.64688 0.46281 0.4726 0.45738
Total Liabilities 9.06445 6.75689 4.56189 4.44829 4.63988
Total Long Term Debt 3.20659 0 0 0 0
Long Term Debt 3.20659
Minority Interest 0.06402 0.13755 -0.22548 -0.15382 -0.06549
Other Liabilities, Total 0.71891 0.79981 0.89306 0.95625 1.04167
Total Equity 1.67049 3.09859 5.91868 9.33432 7.42688
Common Stock 0.03308 0.03286 0.03263 0.03231 0.03031
Additional Paid-In Capital 68.048 67.9075 66.4937 66.2405 62.5785
Retained Earnings (Accumulated Deficit) -56.7281 -54.9044 -50.0405 -46.3356 -44.4766
Treasury Stock - Common -9.1 -9.1 -9.1 -9.1 -9.1
Other Equity, Total -0.58246 -0.83731 -1.4671 -1.50282 -1.60534
Total Liabilities & Shareholders’ Equity 10.7349 9.85548 10.4806 13.7826 12.0668
Total Common Shares Outstanding 33.0807 32.8573 32.6323 32.3073 30.3073
短期投资 0.07801 0.0758 0.07758 0.08276 0.09555
Goodwill, Net 0 0
Preferred Stock - Non Redeemable, Net 0 0 0 0
Note Receivable - Long Term 1.24593 1.14138 1.18996
  • 年度
  • 每季度
2022 2021 2020 2019 2018
净收入/起跑线 -16.3124 -12.0358 -10.5936 -3.93324 -6.06453
经营活动产生的现金 -7.39839 -7.59772 -4.56392 -3.13453 -0.90053
非现金物品 7.38982 5.2157 6.30216 0.22665 3.41079
Cash Taxes Paid 0.0016 0 0 0.00205 0.00185
已付现金利息 0.28547 0.33387 0.20856 0.16713 0.21054
营运资金的变化 0.63557 -1.61376 -0.08643 0.59767 2.07655
融资活动产生的现金 4.01393 9.99555 9.56784 3.08749 0.89686
融资现金流项目 0 -0.85043
股票的发行(报废),净额 3.66393 11.1194 7.61533 1.08411
债务的发行(退还),净额 0.35 -0.27347 1.95251 2.00338 0.89686
现金净变化 -5.17349 1.56384 4.84093 -0.08234 -0.16406
经营活动产生的现金 0.0238 0.01199 0.03714 0.05509 0.04361
Deferred Taxes 0.8648 0.8242 -0.2232 -0.08069 -0.36695
投资活动产生的现金 -1.72168 -0.80597 -0.22543 -0.0353 -0.15637
其他投资现金流量项目,总计 -1.60199 -0.78846 -0.22543 -0.0353 -0.15637
外汇效应 -0.06734 -0.02802 0.06244 0 -0.00402
资本支出 -0.11969 -0.0175
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -1.89723 -16.3124 -11.8115 -8.03495 -6.08762
Cash From Operating Activities -1.49763 -7.39839 -6.93732 -6.42362 -2.99426
Cash From Operating Activities 0.00649 0.0238 0.01736 0.0109 0.00541
Deferred Taxes 0 0.8648 -0.03125 -0.17012 -0.08687
Non-Cash Items 0.36497 7.38982 5.696 4.93657 4.70151
Cash Taxes Paid 0 0.0016 0.0016 0 0
Cash Interest Paid 0.05666 0.28547 0.16174 0.02435 0.04384
Changes in Working Capital 0.02814 0.63557 -0.80797 -3.16603 -1.52669
Cash From Investing Activities 0 -1.72168 -1.6384 -0.11525 -0.09322
Other Investing Cash Flow Items, Total -1.60199 -1.51879 0 0
Cash From Financing Activities 2.20659 4.01393 4.26743 3.66393 0
Issuance (Retirement) of Stock, Net 3.66393 3.91743 3.66393 0
Issuance (Retirement) of Debt, Net 2.20659 0.35 0.35 0 0
Foreign Exchange Effects -0.3088 -0.06734 -0.28678 -0.09103 -0.04515
Net Change in Cash 0.40015 -5.17349 -4.59507 -2.96597 -3.13263
Capital Expenditures 0 -0.11969 -0.1196 -0.11525 -0.09322
Financing Cash Flow Items 0 0
投资者名称 投资者类型 流通股百分比 持有股份 股份变动 持有日期 换手率
YuanGene, Corp Corporation 25.081 8296968 0 2023-05-10 LOW
Jiang (Tsung-Shann) Individual Investor 11.1357 3683784 0 2023-05-10 LOW
Jiang (Eugene) Individual Investor 2.1228 702246 0 2023-05-10 LOW
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 1.1714 387513 12000 2023-03-31 LOW
Odaira (Yoshinobu) Individual Investor 0.4949 163702 0 2023-05-10 LOW
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 0.421 139282 0 2023-03-31 LOW
Two Sigma Investments, LP Hedge Fund 0.139 45973 45973 2023-03-31 HIGH
BlackRock Institutional Trust Company, N.A. Investment Advisor 0.1241 41055 1434 2023-03-31 LOW
Northern Trust Investments, Inc. Investment Advisor/Hedge Fund 0.0557 18421 0 2023-03-31 LOW
Doong (Howard) Individual Investor 0.0556 18404 0 2023-05-10 LOW
Susquehanna International Group, LLP Investment Advisor 0.0421 13923 3897 2023-03-31 MED
Tower Research Capital LLC Hedge Fund 0.0401 13254 -994 2023-03-31 HIGH
Jiang (Tsang Ming) Individual Investor 0.0183 6067 0 2023-05-10 LOW
Chou (Yen-Hsin) Individual Investor 0.0172 5679 0 2023-05-10 LOW
Chung (Yu- Min) Individual Investor 0.0168 5556 0 2023-05-10 LOW
Jiang (Chang-Jen) Individual Investor 0.0168 5545 0 2023-05-10 LOW
Sakamoto (Norimi) Individual Investor 0.0141 4667 0 2023-05-10 LOW
Hsu (Che Wei) Individual Investor 0.0101 3346 0 2023-05-10 LOW
Chow (Leeds) Individual Investor 0.0082 2728 0 2023-05-10 LOW
Lord, Abbett & Co. LLC Investment Advisor 0.0048 1592 0 2023-03-31 MED

为什么选择 Capital.com?让我们的数字来说话。

Capital.com Group

530K+

交易者

87K+

每月活跃客户

$46M+

每月投资额

$31M+

每月提取金额

交易计算器

如果您在特定日期(选择一个日期)开立差价合约交易并在不同日期(选择一个日期)关闭交易,计算您的假设盈亏。

交易佣金
0
  • 1:1
杠杆
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
投资
交易规模(杠杆 x 投资):
開倉

平仓

做空 做多

ABVC BioPharma, Inc. Company profile

关于 ABVC BioPharma Inc.

ABVC生物制药公司(ABVC),前身是美国BriVision(控股)公司,是一家专注于药物和医疗设备开发的生物技术公司。 公司专注于通过跟踪研究机构的医学发现或医疗设备技术来开发其管道。 ABVC有大约六种药物和三种医疗设备正在开发中。 公司的管线包括ABV-1501、ABV-1504、ABV-1505、ABV-1702、ABV-1703、ABV-1601、ABV-1701、ABV-2001和ABV-2002。 ABV-1501是一种治疗三阴性乳腺癌(TNBC)的综合疗法。 ABV-1504是一种针对去甲肾上腺素的植物性再摄取抑制剂。 ABVC正在开发ABV-1505,用于治疗注意力缺陷多动障碍(ADHD)。 ABV-1702是治疗骨髓增生异常综合症(MDS)。 ABVC开发了一个适应症,ABV-1703,用于治疗胰腺癌。 公司已经开发了ABV-1601,用于治疗癌症患者的抑郁症。 ABV-1701是玻璃体切除术的玻璃体替代物。

Industry: Bio Therapeutic Drugs

44370 Old Warm Springs Blvd
FREMONT
CALIFORNIA 94538-6148
US

收入报表

  • Annual
  • Quarterly

人们也观看

XRP/USD

0.49 Price
+2.820% 1D Chg, %
多头隔夜费 -0.0753%
空头隔夜费 0.0069%
隔夜费时间 21:00 (UTC)
价差 0.00373

Gold

1,945.49 Price
-0.050% 1D Chg, %
多头隔夜费 -0.0184%
空头隔夜费 0.0102%
隔夜费时间 21:00 (UTC)
价差 0.30

US100

14,344.10 Price
+0.140% 1D Chg, %
多头隔夜费 -0.0255%
空头隔夜费 0.0032%
隔夜费时间 21:00 (UTC)
价差 1.8

Oil - Crude

73.06 Price
+0.190% 1D Chg, %
多头隔夜费 -0.0146%
空头隔夜费 -0.0073%
隔夜费时间 21:00 (UTC)
价差 0.03

还在找一位您可以信任的经纪商吗?

加入成为全球530,000万多名交易者的一份子,选择利用Capital.com进行交易吧。

1. 创建和验证您的账户 2. 进行存款 3. 找到适合您的交易